EudraCT 2020‐002912‐34.

Study name	Treatment of bullous pemphigoid with avdoralimab (IPH5401), an anti‐C5aR1 monoclonal antibody
Methods	Randomised, controlled clinical trial
Participants	People with autoimmune bullous diseases
Interventions	Avdoralimab (IPH5401) plus super potent topical steroids versus super potent topical steroids
Outcomes	Complete clinical remission, at 3 months
Starting date	11 August 2020
Contact information	Centre Hospitalier Universitaire de Nice, Nice, France Email: caillon.c@chu‐nice.fr Tel. 0033492034589
Notes	Sponsor protocol number: 20‐PP‐13 No further details found